VKTX - VIKING THERAPEUTICS INC.

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program
• Viking Therapeutics EPS miss sends shares down 7%
• Viking Therapeutics GAAP EPS of -$0.58 misses by $0.12
• Viking Therapeutics Q2 2025 Earnings Preview
• Madrigal, Viking among notable gainers after Altimmune’s MASH setback
• SA analyst upgrades: NVDA, DJT, VKTX, BRK.A, BEAM
• Zealand CEO: Oral weight loss meds are not the future for treating obesity
• Viking among notable gainers as Pfizer raises deal prospects
• Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising results
• Viking Therapeutics stock slips after wider than expected Q1 loss
• Viking Therapeutics GAAP EPS of -$0.41 misses by $0.06
• Viking Therapeutics Q1 2025 Earnings Preview
• Why did Lilly data for oral GLP-1 boost Structure and Metsera?
• SA analyst upgrades: AMD, PLTR, VKTX, HUBS, MO, USB, SFIX, VERV
• Eli Lilly jumps as oral GLP-1 drug succeeds in Phase 3 trial
• Viking, Structure, Metsera on a tear as Pfizer drops obesity pill
• Viking Therapeutics draws Neutral rating at Goldman Sachs on competitive headwinds
• SA Asks: Which cardiology drug companies could be takeout candidates?
• Viking Therapeutics inks production deal for obesity drug
• Viking, other obesity players fall following Novo Nordisk CagriSema results